Morepen LaboratoriesNSE:MOREPENLAB +8.16%74 Return-on-Tangible-Equity is 5.59% as of Mar. 2026, which is 70% below its 10-year median of 18.88. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 74/100 and a GF Value™ of ₹49.86 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 897 Drug Manufacturers companies, Morepen Laboratories ranks better than 52.95% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Morepen Laboratories's annualized net income for the quarter that ended in Mar. 2026 was ₹630 Mil. Morepen Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹11,275 Mil. Therefore, Morepen Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.59%.
The historical rank and industry rank for Morepen Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
NSE:MOREPENLAB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 6.87 Med: 18.88 Max: 36.58
Current: 8.83
During the past 13 years, Morepen Laboratories's highest Return-on-Tangible-Equity was 36.58%. The lowest was 6.87%. And the median was 18.88%.
NSE:MOREPENLAB's Return-on-Tangible-Equity is ranked better than 52.95% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs NSE:MOREPENLAB: 8.83
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Morepen Laboratories Return-on-Tangible-Equity Related Terms
Morepen Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.59% mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Return-on-Tangible-Equity of 5.59% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Morepen Laboratories and its competitors. This is 70% below median its historical median of 18.88. Over the past decade, Morepen Laboratories' Return-on-Tangible-Equity has ranged from 6.87 to 36.58. According to the industry distribution chart, Morepen Laboratories ranks #422 out of 897 companies in the Drug Manufacturers industry, placing it in the top 47%.
Is Morepen Laboratories' Return-on-Tangible-Equity too high?
Morepen Laboratories' current Return-on-Tangible-Equity of 5.59% is 70% below median its 10-year median of 18.88. Over the past 10 years, this metric has ranged from a low of 6.87 to a high of 36.58. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Morepen Laboratories' value of 5.59% is 29.2% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #422 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #422 out of 897 companies for Return-on-Tangible-Equity. This puts Morepen Laboratories in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Morepen Laboratories' value of 5.59% is 29.2% below this benchmark. Historically, Morepen Laboratories' own Return-on-Tangible-Equity has ranged from 6.87 to 36.58 over the past decade. While the company's 10-year median is 18.88 vs. the industry median of 7.89, Morepen Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Return-on-Tangible-Equity of 5.59% is 29.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Return-on-Tangible-Equity is 5.59%, which is 70% below median its own 10-year median of 18.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.86, compared to a current price of ₹59.12 — trading 18.6% above its estimated fair value. The current Return-on-Tangible-Equity is 5.59%, which is 70% below median its 10-year median of 18.88 and 29.2% below the Drug Manufacturers industry median of 7.89. Morepen Laboratories' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Return-on-Tangible-Equity is 5.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹59.12 is trading 18.6% above its estimated GF Value™ of ₹49.86.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Return-on-Tangible-Equity: 5.59% (70% below median its 10-year median of 18.88)
GF Value™: ₹49.86 vs. price of ₹59.12 (18.6% above fair value)
Industry Position: 29.2% below the Drug Manufacturers median (#422 of 897)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score
Get the complete analysis for NSE:MOREPENLAB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
